China crackdown on drugmakers' pollution

9 September 2007

China's pharmaceutical manufacturing plants face more rigorous controls on waste disposal after the introduction of the country's first pollution standards tailored for the industry, Reuters reports.

One of the recent spate of food safety concerns in the USA involved the problem of contaminated sea-food from China, where antibiotics that are not approved by the US Food and Drug Administration are used to counter the effects of rearing fish in polluted waters. Phyllis Schlafly, a US conservative commentator, recently quoted the FDA's estimate that a quarter of the shrimp imported into the USA from China are affected. In addition, 51 shipments of Chinese catfish, eel, shrimp and tilapia were rejected by the US authorities because of the presence of salmonella, veterinary drugs and the chemical nitrofuran, a carcinogen.

China's State Environmental Protection Administration has completed a two-month campaign to clean up China's rivers and is now targeting individual factories, the China Daily claimed. In addition, 649 firms have been either closed down or have been forced to suspend operations. The Chinese authorities have also come under pressure following international concerns about pollution, highlighted during ceremonies to mark one year to go before the 2008 Olympic Games in Beijing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight